US Diabetic Retinopathy Market Growth: Technological Advancements in Retinal Imaging and Anti-VEGF Therapies | Leading Companies Include Bayer, Alimera Sciences, and Roche

The Global Diabetic Retinopathy Market reached USD 7,167.00 million in 2023, with a rise to USD 11,702.89 million by 2031, growing at a CAGR of 6.4% during the forecast period (2024-2031). This growth is driven by rising diabetes prevalence, increased awareness of vision-threatening retinal damage, and a surge in advanced treatment options for this serious eye condition.

Diabetic retinopathy, a condition where high blood sugar damages the retina's blood vessels, is a leading cause of blindness in working-age adults. With many patients experiencing little to no symptoms until vision loss has begun, early diagnosis tools such as dilated eye exams, optical coherence tomography (OCT), and fluorescein angiography are becoming critical. Treatments like laser therapy, intraocular steroid injections, and vitrectomy are evolving rapidly. As screening becomes more accessible and therapies more precise, the diabetic retinopathy market is emerging as a key segment in the global ophthalmic care ecosystem, combining innovation with urgent patient need.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/diabetic-retinopathy-market?sai-v

The Diabetic Retinopathy Market focuses on treatments, diagnostics, and technologies aimed at preventing and managing vision loss caused by diabetes-related retinal damage.

Key Players:

=> Major key players in the diabetic retinopathy market are Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals, Bayer AG, Hoffmann-La Roche, Novartis International AG, Glycadia Pharmaceuticals, Regeneron Pharmaceuticals Inc and Valeant Pharmaceutical.

Key Developments: Diabetic Retinopathy (U.S. & Japan)

♦ January 2025 (Japan): Santen Pharmaceutical initiated post-approval clinical programs for its long-acting anti-VEGF formulation, aiming to reduce injection frequency and enhance adherence in diabetic retinopathy and diabetic macular edema patients.

♦ September 2024 (U.S.): Regeneron reported positive Phase III outcomes for EYLEA HD (8 mg aflibercept), supporting dosing intervals of up to 16 weeks, improving patient convenience and treatment outcomes.

♦ January 2024 (Japan): Japan's Ministry of Health, Labour and Welfare approved the 8 mg aflibercept (EYLEA®) formulation for diabetic macular edema associated with diabetic retinopathy, introducing extended treatment intervals for clinical use.

Recent Mergers & Strategic Moves: Diabetic Retinopathy (U.S. & Japan)

♦ July 2025 (U.S.): Harrow Inc. completed the acquisition of exclusive U.S. rights from Samsung Bioepis for its ophthalmology biosimilar portfolio, including OPUVIZTM (aflibercept biosimilar) for diabetic retinopathy.

♦ May 2024 (U.S.): Merck & Co. acquired EyeBio Ltd. in a deal valued up to USD 3 billion, strengthening its late-stage ophthalmology pipeline targeting retinal vascular disorders such as diabetic retinopathy.

♦ March 2024 (Japan): Otsuka Pharmaceutical formed a collaboration with Riken and Keio University to advance gene-modulating therapeutic approaches for diabetic retinopathy, focusing on vascular protection and neuroinflammation control.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=diabetic-retinopathy-market?sai-v

Market Drivers - Diabetic Retinopathy Market

Rising Diabetes Cases: Growing global diabetes prevalence increases DR incidence.

Aging Population: Older demographics and sedentary lifestyles heighten risk.

Early Detection Initiatives: Government and private programs boost screening rates.

Tech Advancements: AI-based imaging and improved anti-VEGF therapies enhance diagnosis and treatment.

Healthcare Support: Expanding infrastructure and reimbursement policies drive market growth.

Industry Developments - Diabetic Retinopathy Market

AI-Powered Diagnostics: Wider use of AI for automated DR screening.

Long-Acting Drugs: Sustained-release anti-VEGF agents improving patient compliance.

Emerging Market Expansion: Asia-Pacific witnessing rapid adoption of DR treatments.

Innovative Surgeries: Advances in laser and vitrectomy techniques improving outcomes.

Collaborations: Pharma-tech partnerships accelerating new DR solutions.

Research Process:

Both primary and secondary data sources have been used in the Global Diabetic Retinopathy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Key Segments:

➥ By Indication Type: Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
➥ By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Drug, Intraocular Steroid Injection, Laser Surgery, Vitrectomy
➥ By End User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/diabetic-retinopathy-market?sv

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.